# 2026-10188: FDA Reviews Drug Factory Record-Keeping Forms

2026-10188, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-21, effective Submit written comments (including recommendations) on the collection of information by June 22, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-10188
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-10188
- Title: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 29968
- Published: 2026-05-21
- Effective: Submit written comments (including recommendations) on the collection of information by June 22, 2026.
- Comments close: 2026-06-22
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Reviews Drug Factory Record-Keeping Forms

## Summary

The FDA is updating how it collects info about drug making to keep medicines safe and high-quality. This affects drug makers who must follow good manufacturing rules and may see some changes in paperwork. Comments on these updates are open until June 22, 2026, so industry folks have time to weigh in before any new rules kick in.

## Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Effects PRIA read

- Medical Gas Burden Removed: benefit, high. FDA removed medical gas information-collection requirements from this OMB control number, shifting them to 0910-0906. That removal reduces annual burden by 396,293 hours and 639,491 responses.
- Recordkeeping Burden for Drug Makers: cost, high. FDA estimates API manufacturers (1,260 recordkeepers) have 322,560 records requiring 264,499 hours annually (0.82 hours per record). Finished pharmaceuticals manufacturers (3,270 recordkeepers) have 977,730 records requiring 625,747 hours annually (0.64 hours per record), for a total of 1,300,319 r…
- AMT Designation Information Burden: cost, low. The information collection covers FDA's Advanced Manufacturing Technologies (AMT) Designation Program and estimates 20 designation requests totaling 200 hours (10 hours per request). FDA notes the AMT activity was omitted from a prior summary and is now included.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-10188 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/21/2026-10188/agency-information-collection-activities-submission-for-office-of-management-and-budget-review)
- [2026-10188 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-21/pdf/2026-10188.pdf)

## Related
- [Previous: 2026-10187, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-10187)
- [Next: 2026-10189, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-10189)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-10188 (as of 2026-06-08).
